Michael D. Hambuchen, Ph.D. - Publications

Affiliations: 
2013 Pharmacology University of Arkansas for Medical Sciences, United States 
Area:
Pharmacology

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Berquist MD, McGill MR, Mazur A, Findley DL, Gorman G, Jones CB, Hambuchen MD. Effect of bile duct ligation-induced liver dysfunction on methamphetamine pharmacokinetics in male and female rats. Drug and Alcohol Dependence. 215: 108190. PMID 32736295 DOI: 10.1016/j.drugalcdep.2020.108190  0.339
2020 Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse. The Journal of Pharmacology and Experimental Therapeutics. PMID 32245884 DOI: 10.1124/Jpet.119.261180  0.532
2019 McClenahan SJ, Kormos CM, Gunnell M, Hambuchen MD, Lamb P, Carroll FI, Lewin AH, Peterson EC, Owens SM. Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats. Vaccine. PMID 31629568 DOI: 10.1016/J.Vaccine.2019.10.008  0.553
2019 Hambuchen MD, Berquist MD, Simecka CM, McGill MR, Gunnell MG, Hendrickson HP, Owens SM. Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques. 22: 301-312. PMID 31329536 DOI: 10.18433/Jpps30471  0.468
2019 McClenahan SJ, Hambuchen MD, Simecka CM, Gunnell MG, Berquist MD, Owens SM. Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats. Drug and Alcohol Dependence. 195: 140-147. PMID 30634109 DOI: 10.1016/J.Drugalcdep.2018.12.006  0.612
2018 Hay CE, Gonzalez GA, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, Peterson EC. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse. Plos One. 13: e0200060. PMID 29958300 DOI: 10.1371/Journal.Pone.0200060  0.522
2017 Hambuchen MD, Hendrickson HP, Gunnell MG, McClenahan SJ, Ewing LE, Gibson DM, Berquist MD, Owens SM. The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats. Drug and Alcohol Dependence. 179: 347-354. PMID 28844011 DOI: 10.1016/J.Drugalcdep.2017.07.011  0.566
2017 Hambuchen MD, Hendrickson HP, Owens SM. Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum. Analytical Methods : Advancing Methods and Applications. 9: 609-617. PMID 28286575 DOI: 10.1039/C6Ay03176E  0.516
2016 Hambuchen MD, Rüedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic Treatment of (+)-Methamphetamine-Induced Locomotor Effects in Rats Using One or a Combination of Two High Affinity Anti-Methamphetamine Monoclonal Antibodies. Human Vaccines & Immunotherapeutics. 0. PMID 27163775 DOI: 10.1080/21645515.2016.1179407  0.597
2015 Hambuchen MD, Carroll FI, Rüedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. Journal of Medicinal Chemistry. 58: 4665-77. PMID 25973614 DOI: 10.1021/Acs.Jmedchem.5B00220  0.521
2015 Milesi-Hallé A, Hambuchen MD, McMillan DE, Michael Owens S. The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug and Alcohol Dependence. 150: 164-9. PMID 25796510 DOI: 10.1016/J.Drugalcdep.2015.02.032  0.54
2014 Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Human Vaccines & Immunotherapeutics. 10: 2638-47. PMID 25483484 DOI: 10.4161/Hv.29707  0.591
2014 Peterson EC, Hambuchen MD, Tawney RL, Gunnell MG, Cowell JL, Lay JO, Blough BE, Carroll FI, Owens SM. Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages. Bioconjugate Chemistry. 25: 2112-5. PMID 25426820 DOI: 10.1021/bc500456z  0.381
2014 Hambuchen MD, Rüedi-Bettschen D, Williams DK, Hendrickson H, Owens SM. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. Vaccine. 32: 6213-9. PMID 25252196 DOI: 10.1016/J.Vaccine.2014.09.025  0.631
2014 Hambuchen MD, Rüedi-Bettschen D, Hennings L, Owens S. Combining active and passive antibody therapy to facilitate initiation and long-term treatment of methamphetamine abuse in a rat model of addiction Drug and Alcohol Dependence. 140: e78. DOI: 10.1016/J.Drugalcdep.2014.02.231  0.408
2011 Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. Cns & Neurological Disorders Drug Targets. 10: 892-8. PMID 22229314 DOI: 10.2174/187152711799219370  0.521
Show low-probability matches.